SCOTTSDALE, Ariz., Aug. 11, 2009 (GLOBE NEWSWIRE) -- TASER International, Inc. (Nasdaq:TASR), a leading provider of technology solutions and the market leader in electronic control devices (ECDs), announced that three (3) arrest-related death lawsuits were dismissed against TASER International. No monies were paid by TASER International to plaintiffs for these dismissals.
In the first lawsuit, the United States District Court for the District of Nevada issued an order in the arrest-related death lawsuit entitled Walker v. TASER International, et al. granting TASER International's motion for summary judgment and also granting TASER International's motion to exclude the testimony of Plaintiff's purported expert, Dr. Erik Sirulnick.
In the second lawsuit, the Superior Court for the County of Sacramento, California entered an order, based on a stipulation of the parties, dismissing without prejudice TASER International from the arrest-related death litigation entitled Zaragoza v. TASER International, et al.
In the third lawsuit, the United States District Court for the Southern District of Florida entered an order, based on a stipulation of the parties, dismissing with prejudice TASER International from the arrest-related death litigation entitled Bolander v. TASER International, et al.
"The court's ruling granting TASER's summary judgment in the Walker case is especially notable since the court also ordered the exclusion of Dr. Sirulnick's testimony due to a lack of scientific reliability," said Doug Klint, Executive Vice President and General Counsel of TASER International. "In addition, the fact that the plaintiffs in the Bolander and Zaragoza litigations voluntarily dismissed these lawsuits is indicative of the strong medical and scientific evidence that the TASER(r) device did not cause these unfortunate deaths. TASER International will continue to aggressively defend all litigation filed against the Company," continued Klint.
About TASER International, Inc.
TASER International's products protect life. TASER provides advanced Electronic Control Devices (ECDs) for use in the law enforcement, medical, military, corrections, professional security, and personal protection markets. TASER devices use proprietary technology to incapacitate dangerous, combative, or high-risk subjects who pose a risk to law enforcement officers, innocent citizens, or themselves in a manner that is generally recognized as a safer alternative to other uses of force. For more information please call TASER International at (800) 978-2737 or visit our website at www.TASER.com.
The TASER International logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2931
Note to Investors
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding our expectations, beliefs, intentions or strategies regarding the future. We intend that such forward-looking statements be subject to the safe-harbor provided by the Private Securities Litigation Reform Act of 1995. The forward-looking information is based upon current information and expectations regarding TASER International. These estimates and statements speak only as of the date on which they are made, are not guarantees of future performance, and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results could materially differ from what is expressed, implied, or forecasted in such forward-looking statements.
TASER International assumes no obligation to update the information contained in this press release. These statements are qualified by important factors that could cause our actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) market acceptance of our products; (2) our ability to establish and expand direct and indirect distribution channels; (3) our ability to attract and retain the endorsement of key opinion-leaders in the law enforcement community; (4) the level of product technology and price competition for our products; (5) the degree and rate of growth of the markets in which we compete and the accompanying demand for our products; (6) risks associated with rapid technological change and new product introductions; (7) competition; (8) litigation including lawsuits resulting from alleged product related injuries and death; (9) media publicity concerning allegations of deaths and injuries occurring after use of the TASER device and the negative effect this publicity could have on our sales; (10) TASER device tests and reports; (11) product quality; (12) implementation of manufacturing automation; (13) potential fluctuations in our quarterly operating results; (14) financial and budgetary constraints of prospects and customers; (15) order delays; (16) dependence upon sole and limited source suppliers; (17) negative reports concerning the TASER device; (18) fluctuations in component pricing; (19) government regulations and inquiries; (20) dependence upon key employees and our ability to retain employees; (21) execution and implementation risks of new technology; (22) ramping manufacturing production to meet demand; (23) medical and safety studies; (24) field test results; and (25) other factors detailed in our filings with the Securities and Exchange Commission, including, without limitation, those factors detailed in the Company's Annual Report on Form 10-K and its Form 10-Qs.
The statements made herein are independent statements of TASER International. The inclusion of any third parties does not represent an endorsement of any TASER International products or services by any such third parties.